Intranasal vaccines employing live attenuated viruses or viral vectors offer promising prospects by simultaneously eliciting mucosal IgA, systemic IgG, and T cell responses, thereby preventing both infection and transmission [32,263,382,383]. This evidence concerns the gene CD79A and infection.